GlassScriptPhysician profile
Lily Kao
NPI 1578742888
$18,875.28
in general payments reported to CMS, 2019-2025
57 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,206 · 2020: $1,792 · 2021: $2,383 · 2022: $2,851 · 2023: $3,135 · 2024: $3,414 · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,536 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,536.30 |
| Education | $107.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,718.99 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $2,377.19 | 2019-2025 | |
| Pfizer INC. | $1,284.44 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $1,235.42 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $1,184.95 | 2019-2025 | Tremfya, Stelara, Remicade |
| Glaxosmithkline, LLC. | $973.78 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $911.89 | 2019-2025 | Saphnelo |
| Radius Health, INC. | $760.97 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $693.78 | 2019-2025 | |
| Ucb, INC. | $638.78 | 2022-2025 | Bimzelx, Cimzia |
| Ibsa Pharma INC. | $526.31 | 2019-2025 | Licart, Tirosint, Tirosint |
| Novo Nordisk INC | $408.88 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $361.33 | 2019-2025 | Taltz, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $344.84 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Alexion Pharmaceuticals, INC. | $332.62 | 2019-2025 | Strensiq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.